MetaVia Phase 2a vanoglipel shows HbA1c -0.54%p, ALT reductions in MASH trial

MetaVia Inc.

At Week 16, vanoglipel monotherapy reduced HbA1c by 0.54%p and combination therapy by 0.66%p from baseline 6.99% (p<0.05 vs placebo).
Vanoglipel significantly decreased plasma ALT in patients with baseline ALT 40-200 U/L, with hepatoprotective effects driven by monotherapy.
Improvements in liver steatosis (CAP), stiffness (VCTE), and non-invasive scores (FAST, NIS-4) were observed at 16 weeks.
Circulating biomarkers of cell death (CK18F/M30), inflammation (hs-CRP, CCL2), and fibrosis (TIMP1) were reduced.
Vanoglipel 100 mg reduced pathogenic glycerolipids and glycerophospholipids; well tolerated with no discontinuations except one placebo.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.